MSLN and neoplasm: Based on the promising results obtained from MSLN mAbs, immunotoxins, and ADCs, there is a growing interest in exploring MSLN as a target for CAR-T cell therapy, where T-cells are manipulated to produce variable chain/T-cell receptor hybrid so that cancer cell is recognized by CAR-T cell binding to the tumor antigen, which activates T-cell signaling and results in cancer-cell killing.